Global Endometrial Cancer Therapeutics Markets 2018-2022 - Key Vendors are Celgene, Janssen Pharmaceuticals, Novartis, Pfizer & Teva Pharmaceutical Industries - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Global Endometrial Cancer Therapeutics Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
The Global Endometrial Cancer Therapeutics Market to grow at a CAGR of 5.17% during the period 2018-2022.
Global Endometrial Cancer Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Endometrial cancer is a type of uterine cancer, which begins in the layer of cells that form the lining (endometrium) of the uterus of women. Unopposed endometrial estrogen exposure such as estrogen replacement therapy during menopause is associated with increased risk of developing endometrial cancer among women.
According to the report, one driver influencing this market is the increasing prevalence of endometrial cancer. The prevalence of endometrial cancer has been increasing rapidly due to the changing lifestyle, which is contributing to the growth of the market across the globe. One trend affecting this market is immune therapy. Immune therapy, also known as biological therapy, is a type of cancer treatment that improves the defense mechanism of the body to fight against the cancer.
Further, the report states that one challenge affecting this market is the high cost associated with treatment. One of the most major challenges being faced in the global endometrial cancer therapeutics market is the high cost of treatment such as chemotherapy, lab tests, and oral medications.
Key vendorsCelgene Janssen Pharmaceuticals Novartis Pfizer Teva Pharmaceutical Industries
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 05: MARKET SIZING 2017-2022
PART 06: FIVE FORCES ANALYSIS
PART 07: PIPELINE
PART 08: MARKET SEGMENTATION BY PRODUCTSegmentation by product Comparison by product Chemotherapy Hormone therapy Market opportunity by product
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPEGeographical segmentation Regional comparison Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGESMarket drivers Market challenges
PART 13: MARKET TRENDSImmune therapy Personalized medicine Increase in small molecules in drug development pipeline
PART 14: VENDOR LANDSCAPEOverview Landscape disruption
PART 15: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors
For more information about this report visit https://www.researchandmarkets.com/research/f2vdtv/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005843/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Uterine Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/25/2018 10:57 AM/DISC: 09/25/2018 10:57 AM